Dr.Ethix'S Products And Services Profile
Key Indicators
- Authorised Capital ₹ 1.15 Cr
- Paid Up Capital ₹ 1.15 Cr
- Company Age 5 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.10 M
About Dr.Ethix'S Products And Services
Dr.Ethix's Products And Services Limited (DPASL) is a Public Limited Indian Non-Government Company incorporated in India on 13 June 2019 (Five years and seven months 21 days old ). Its registered office is in Chennai, Tamil Nadu, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.15 Cr and a paid-up capital of Rs 1.15 Cr.
The company currently has active open charges totaling ₹2.10 M.
Daniel Muniappan, Joy Gethsy, Arun Thomas, and Three other members serve as directors at the Company.
Company Details
-
Location
Chennai, Tamil Nadu, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U24100TN2019PLC129889
-
Company No.
129889
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
13 Jun 2019
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Dr.Ethix'S Products And Services?
Board Members (6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Daniel Muniappan
|
Director | 13-Jun-2019 | Current |
|
Joy Gethsy
|
Director | 13-Jun-2019 | Current |
|
Arun Thomas
|
Director | 27-May-2023 | Current |
| Sant Lal | Additional Director | 13-May-2024 | Current |
| Nand Sharma | Additional Director | 13-May-2024 | Current |
| Nathamuni Vasanthakumar | Additional Director | 13-May-2024 | Current |
Financial Performance of Dr.Ethix'S Products And Services.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dr.Ethix'S Products And Services?
Unlock access to Dr.Ethix'S Products And Services's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Stamin Millennium Nutraceuticals Private LimitedDaniel Muniappan and Arun Thomas are mutual person
Charges (Loans)
₹0.21 Cr
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.21 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 14 Feb 2023 | Hdfc Bank Limited | ₹2.10 M | Open |
How Many Employees Work at Dr.Ethix'S Products And Services?
Unlock and access historical data on people associated with Dr.Ethix'S Products And Services, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dr.Ethix'S Products And Services, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dr.Ethix'S Products And Services's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.